Article Per Year (5 Year)
p-Index From 2020 - 2025
1.037
P-Index
This Author published in this journals
All Journal Indonesian Journal of Pharmacology and Therapy
Woro Rukmi Pratiwi
Unknown Affiliation
Immunology & microbiology Medicine & Pharmacology

Published : 5 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 5 Documents
Search

 1 
Expression of VEGF-A And COX-2 mRNA in non-steroidal anti-inflammatory drugs treated rat primary colonic fibroblast Andrew Limavanady; Jonathan J; Gloria Evita Thalia; Rasya Mayora; Ade Saputri; Rahmi Ayu Wijayaningsih; Eko Purnomo; Fara Silvia Yuliani; Woro Rukmi Pratiwi; Dwi Aris Agung Nugrahaningsih
Indonesian Journal of Pharmacology and Therapy Vol 1 No 1 (2020)
Publisher : Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada and Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFARI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/ijpther.508

Abstract

Non-steroidal anti-inflammatory drugs (NSAIDs) is often used to shorten recovery time after surgery, including after colon anastomosis surgery. Studies showed that NSAIDs might involve in the development of colon anastomotic leakage. However, the effect of NSAIDs in colon anastomosis leakage is still a subject of controversy. Studies indicated that selectivity of COX-2 might have a role in the deleterious effect of NSAIDs in colon anastomosis. Disruption of VEGF-A by NSAIDs also suspected to be the culprit in the development of anastomosis leakage during NSAIDs treatment. This study aimed to investigate the NSAIDs effect toward VEGF-A and COX-2 mRNA in rat primary colonic fibroblast. The in vitro study was conducted using fibroblast isolated from rat colon. The isolated fibroblast was divided into 4 groups of treatment i.e.controlgroup, acetaminophen group, metamizole group, and ketorolacgroup. After 48 h of treatment, the cell was harvested and the RNA was isolated. The expression of VEGF-A and COX-2 mRNA was conducted using semi-quantitative PCR(sq-PCR). Both VEGF-A and COX-2 were not expressed in untreated rat colon fibroblast. However, VEGF-A mRNA washighly expressed in the ketorolacgroup. Interestingly, COX-2 mRNA couldbe seen in the ketorolac and metamizole groups but not in the acetaminophen group. The COX-2 mRNA expression wasthe highest in ketorolac treated rat colon fibroblast. It can be concluded that the effect of various kinds of NSAIDs towards VEGF-A and COX-2 mRNA expression of colon fibroblasts is different. This condition is duetotheir different inhibitory selectivity towards COX-1 and COX2.
Drugs repurposing for COVID-19: phase III clinical trial evaluation Woro Rukmi Pratiwi
Indonesian Journal of Pharmacology and Therapy Vol 2 No 1 (2021)
Publisher : Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada and Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFARI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/ijpther.1228

Abstract

World Health Organization (WHO) has announced coronavirus disease 2019 (COVID-19) as a global pandemic which is the largest public health crisis in this century. The spread of COVID-19 is still not well-controlled even become global health threat. As new disease, the specific drugs for COVID-19 have not been available, yet. Face of this condition, repurposing existing drugs become the best options in order to meet the urgently need of the effective drugs. In this article, the clinical trial results of some drugs for the treatment of COVID-19 included hydroxychloroquine, chloroquine, lopinavir/ritonavir, remdesivir, oseltamivir, favipiravir, and corticosteroids were reviewed. Hydroxychloroquine, choloquine and lopinavir/ritonavir were shown to be ineffective. Therefore, they were excluded from the list of drugs for the tratment of COVID-19 by WHO and the National Agency of Drug and Food Control of Republic of Indonesia (NCDE NA-DFC RI). Furthermore, NA-DFC RI has issued an emergency use authorization (EUA) for the use of remdesivir and favipiravir for the treatment of COVID-19.
The comparison of colchicine and standard treatment in COVID-19 patients: A mini review Kwok, Yasmeen; Dwi Aris Agung Nugrahaningsih; Woro Rukmi Pratiwi
Indonesian Journal of Pharmacology and Therapy Vol 2 No 3 (2021): Special Issue: COVID-19
Publisher : Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada and Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFARI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/ijpther.2381

Abstract

Coronavirus disease 2019 (COVID-19) was declared a pandemic in March 2020. There are several drugs used at different stages of the disease, but none seem to be completely effective. In the absence of any known therapy, many drugs have been tested, including colchicine. Colchicine differs from these other therapies in having pleiotropic mechanism of action, being less potent on any single target, and being an oral agent. It is also a better option since colchicine is not immunosuppressive, is not known to increase risk of infection, and is inexpensive. The aim of this study was to provide evidence of the role of colchicine in improving clinical outcome and reducing death rate of COVID-19 patients through literature mini-review. A mini-review, composed of previous RCTs comparing the use of colchicine in COVID-19 with standard care or placebo under the keyword “COVID-19”, “COVID”, “coronavirus”, “SARS-CoV-2”, “coronavirus disease”, “Colchicine”, “CAS 64-86-8”, “standard treatment”, “standard care”, “standard of care”, “common treatment”, “placebo”, “clinical improvement”, and “clinical response”. The addition of colchicine to standard treatment can be beneficial in treating COVID-19. Studies included showed that colchicine has significantly improved time to clinical deterioration compared to the control group. Colchicine reduced the length of hospitalization and the need for supplemental oxygen therapy. One of the included studies mentioned that in outpatient settings, colchicine can prevent hospitalization and even death. Colchicine can improve the clinical outcome on CRP levels, the number of patients that need mechanical ventilation, and death rate in COVID-19 patients. The addition of colchicine to standard treatment should be considered to prevent clinical deterioration and death. Colchicine reduces the number of adverse effects in COVID-19 patients except for gastrointestinal adverse effects, especially diarrhea, which is consistently more common in the colchicine groups.
Cytotoxic activity of hantap (Sterculia oblongata Mast) leaves extract against breast cancer cells line (MCF7/HER2): the effect on the expression of HER2 mRNA and the apoptosis Sitti Ayu Suhartina Yahya; Mustofa; Woro Rukmi Pratiwi; Adika Suwarman
Indonesian Journal of Pharmacology and Therapy Vol 3 No 1 (2022)
Publisher : Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada and Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFARI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/ijpther.3204

Abstract

Hantap leaves (Sterculia oblongata Mast) has been used traditionally to treat breast cancer in Palu, Central Sulawesi. However, its use is just based on empirical evidences rather than scientific evidences. The study aimed to investigate the cytotoxic activity of hantap leaves extracts against breast cancer cells line. The effect of this extract on the HER2 expression and the apoptosis was also evaluated. The hantap (S. oblongata Mast) leaves extracts were prepared by consecutive maceration method using n-hexane, methanol and water, respectively. The cytotoxic activity against MCF7/HER2 breast cancer cells line was evaluated using the MTT assay with doxorubicin as a positive control. The HER2 mRNA expression was examined using RT-PCR and the apoptosis after 24 h incubation was examined using a fluorescence microscope after AO-PI (acridine orange-propidium iodide) staining. Among three extracts tested, the methanolic extract exhibited the most cytotoxic against MCF7/HER2 cells with an IC50 of 91.25 μg/mL. Therefore, the methanolic extract was subjected to further study. The methanolic extract at concentration of 1/2IC50; 1IC50 and 2IC50 μM induced 6.8; 26.3 and 25.3% apoptosis of the MFC7/HER2 cell lines, respectively. The methanolic extract at concentration of 1/2IC50; 1IC50 and 2IC50 μM inhibited HER2 mRNA expression to be 0.6; 0.25 and 0.33 compared to control cells. In conclusion, the methanolic extract of hantap leaves (S. oblongata Mast) has cytotoxic activity against MCF7/HER2 breast cancer cell lines by induce cells apoptosis and inhibit HER2 mRNA expression. Further study, will be conducted to isolate active constituents as anticancer.
Cytotoxicity of hantap (Sterculia oblongata Mast) leaves extracts against breast cancer cell line (T47D): effect on apoptosis and caspase-3 mRNA expression Adika Suwarman; Indwiani Astuti; Woro Rukmi Pratiwi; Sitti Ayu Suhartina Yahya
Indonesian Journal of Pharmacology and Therapy Vol 5 No 2 (2024)
Publisher : Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada and Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFARI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/ijpther.10147

Abstract

Hantap (Sterculia oblongata Mast) leaves has been traditionally used in Palu, Central Sulawesi to treat breast cancer. However, its scientific evidence is limited. This study aimed to investigate the cytotoxicity of hantap leaf extracts against T47D breast cancer cells. The apoptotic activity of the extracts and its effect on caspase expression were also evaluated. The extracts were prepared by multilevel maceration using n-hexane, methanol, and water. Cytotoxic activity was evaluated by MTT assay. The apoptotic activity was observed by using a fluorescence microscope after acridine orange-propidium iodide (AO/PI) staining, whereas the caspase-3 mRNA expression was examined by using RT-PCR. Among the 3 tested extracts, the methanol extract exhibited the highest cytotoxicity with an IC50 value of 85 μg/mL. The methanol extract at concentrations of 42.5 μg/mL (½IC50), 85 μg/mL (IC50), and 170 μg/mL (2IC50) induced 127.25, 85.50, 479.5% of cell apoptosis, respectively. Furthermore, the methanol extract at concentrations of ½IC50, IC50, and 2IC50 increased 1.04, 1.43 and 1.69 time higher of caspase-3 mRNA expression. In conclusion, the methanolic extract of hantap leaf exhibits cytotoxicity against T47D breast cancer cells, by inducing apoptosis and increasing caspase-3 mRNA expression.
Co-Authors Ade Saputri Adika Suwarman Andrew Limavanady Dwi Aris Agung Nugrahaningsih eko purnomo Gloria Evita Thalia Indwiani Astuti Jonathan J Kwok, Yasmeen Mustofa Mustofa Rahmi Ayu Wijayaningsih Rasya Mayora Sitti Ayu Suhartina Yahya Yuliani, Fara Silvia